Lotus Pharmaceutical Co Ltd (1795) — Cash Flow Quality Index
Lotus Pharmaceutical Co Ltd (1795) has a Cash Flow Quality Index of 1.03x as of December 2025. Operating cash flow of NT$1.35 Billion exceeds net income of NT$1.32 Billion, indicating high earnings quality where cash backs reported profits. Explore debt repayment capacity of Lotus Pharmaceutical Co Ltd to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Lotus Pharmaceutical Co Ltd Cash Flow Quality Index (2009–2025)
Historical Cash Flow Quality Index for Lotus Pharmaceutical Co Ltd across 14 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see 1795 cash flow metrics.
Annual Cash Flow Quality Index for Lotus Pharmaceutical Co Ltd (2009–2025)
Year-by-year earnings quality comparison for Lotus Pharmaceutical Co Ltd.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.31x | NT$7.48 Billion | NT$5.72 Billion | ▲ +35.2% |
| 2024 | 0.97x | NT$6.15 Billion | NT$6.36 Billion | ▲ +146.2% |
| 2023 | 0.39x | NT$1.61 Billion | NT$4.11 Billion | ▼ -58.3% |
| 2022 | 0.94x | NT$3.72 Billion | NT$3.94 Billion | ▲ +1375.2% |
| 2021 | 0.06x | NT$119.66 Million | NT$1.87 Billion | ▼ -95.7% |
| 2020 | 1.49x | NT$1.95 Billion | NT$1.30 Billion | ▲ +332.4% |
| 2019 | 0.35x | NT$302.81 Million | NT$876.42 Million | ▼ -92.9% |
| 2018 | 4.87x | NT$796.98 Million | NT$163.70 Million | ▲ +73.3% |
| 2017 | 2.81x | NT$592.29 Million | NT$210.81 Million | ▼ -95.6% |
| 2016 | 64.02x | NT$1.23 Billion | NT$19.26 Million | ▲ +1711.2% |
| 2015 | 3.53x | NT$1.08 Billion | NT$304.87 Million | ▲ +181.8% |
| 2013 | -4.32x | NT$-95.84 Million | NT$22.19 Million | ▼ -209.8% |
| 2010 | 3.93x | NT$59.19 Million | NT$15.05 Million | ▼ -86.3% |
| 2009 | 28.71x | NT$89.50 Million | NT$3.12 Million | — |